Zydus Lifesciences Ltd - 532321 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Zydus Life Science received a USFDA Warning Letter for its Baddi facility. The letter addresses technical observations related to purified talc not meeting USP requirements, but the company anticipates no impact on current operations or supplies.
Jun 03 2026 10:31:17
Zydus Lifesciences Ltd - 532321 - Corporate Action-Updates on Buy back
Zydus Life Sciences announced a buyback of up to 87.30 lakh shares for an aggregate amount not exceeding Rs.1,100 cr, at a price of Rs.1,260 per share via a tender offer. The record date for the buyback is May 29, 2026, with promoters planning to participate.
Jun 01 2026 17:19:30
Zydus Lifesciences Ltd - 532321 - Corporate Action-Updates on Buy back
Zydus Life Science announced a buyback offer for up to 87.30 lakh equity shares at Rs. 1,260 each, aggregating Rs. 1,100 crore. The buyback aims to return surplus cash to shareholders and enhance return on equity.
May 31 2026 20:27:41
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Life Science received US FDA Priority Review for its Saroglitazar New Drug Application (NDA) for Primary Biliary Cholangitis. This accelerates the review process, with a PDUFA target action date of November 27, 2026, and potential US launch in Q4 FY27 if approved.
May 28 2026 18:08:18
Zydus Lifesciences Ltd - 532321 - Corporate Action-Updates on Buy back
Zydus Life Science has increased its buyback price to Rs.1,260 per equity share from the earlier Rs.1,150, representing a 9.5% increase. Concurrently, the maximum number of shares to be bought back has been reduced from 95.65 lakh to 87.30 lakh, accounting for up to 0.87% of paid-up capital.
May 28 2026 14:26:33
Zydus Lifesciences Ltd - 532321 - Corporate Action-Updates on Buy back
Zydus Life Science revised the terms of its ongoing buyback offer. The buyback price has been increased to Rs.1,260 per share, while the maximum number of shares to be acquired has been reduced to 87.30 lakh, representing 0.87% of capital.
May 27 2026 18:17:01
Zydus Lifesciences Ltd - 532321 - Update
Zydus Lifesciences' subsidiary, Zydus Therapeutics, received US FDA Priority Review for its New Drug Application (NDA) for saroglitazar. The drug is intended for Primary Biliary Cholangitis (PBC) treatment, signaling an expedited review process.
May 27 2026 17:29:19
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Zydus Life Science will participate in the Bank of America India Conference in Mumbai on June 2, 2026. This meet provides an opportunity for direct engagement with analysts and investors.
May 23 2026 15:34:49
Zydus Lifesciences Ltd - 532321 - Corporate Action-Updates on Buy back
Zydus Life Sciences announced a buyback of 95.65 lakh equity shares at Rs.1,150 per share, with an aggregate value of Rs.1,100 crores. The buyback will be conducted through a tender offer, signaling confidence in the company's valuation.
May 21 2026 13:02:10
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Zydus Life Science has released the audio recording of its investor call. The call discusses the audited financial results for the quarter and year ended March 31, 2026, and is available on the company's website.
May 19 2026 19:31:46
Read More